Pharmaceuticals

MALAYSIA HEALTHCARE DEEPENS BANGLADESH PRESENCE AS MEDICAL TOURISM DEMAND GROWS

CHATTOGRAM, Bangladesh, Sept. 21, 2026 /PRNewswire/ -- Malaysia Healthcare Travel Council (MHTC) deepened its engagement in Bangladesh through Malaysia Healthcare Week in Bangladesh, held from 16 to 21 September, bringing Malaysian hospitals and healthcare stakeholders together across Dhaka and C...

2026-09-21 10:41 2394

Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse

* Transformational merger reinforces Telix's long-term growth strategy as a vertically integrated radiopharmaceutical company with enhanced capabilities across development, isotope production and global manufacturing, underpinned by commercial excellence and the industry's most extensive therap...

2026-09-21 09:59 2449

New Option To Support Cervical Health In Women With HPV In Singapore

Colpofix®, a vaginal spray gel medical device, supports the regression of HPV-related cervical lesions SINGAPORE, Sept. 21, 2026 /PRNewswire/ -- Women in Singapore now have another option to support their cervical health following Human Papillomavirus (HPV) infection, with DKSH's launch of Colpo...

2026-09-21 09:00 2450

Antengene Announces First Patient Dosed in Pivotal Phase III CLINCH-3 Study of ATG-022

SHANGHAI and HONG KONG, Sept. 21, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune di...

2026-09-21 08:30 2039

Specialised Therapeutics Expands Partnership with Incyte to Include Ruxolitinib Cream (Opzelura®) in Australia

SINGAPORE, Sept. 20, 2026 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics (ST)today announced an expansion of its existing partnership with Incyte Biosciences International, an affiliate of Incyte (NASDAQ: INCY), to commercialise, distribute, and register ruxolitini...

2026-09-21 04:00 2785

S2S China Announces 2026 Finalists, Ten Standout Teams Set to Pitch Global Investors at Westlake University

SHANGHAI, Sept. 20, 2026 /PRNewswire/ -- The inaugural S2S China Symposium has announced the finalists of its 2026 program. Co-hosted by RA Capital Management and Qiming Venture Partners, S2S China is the China chapter of Science2Startup, an invitation-only symposium connecting top academic resea...

2026-09-20 20:24 3253

Accro Bioscience Announces First Patient Dosed in Phase IIb Study of AC-101 in Moderate-to-Severe Ulcerative Colitis

NEW YORK and SUZHOU, China, Sept. 20, 2026 /PRNewswire/ -- Accro Bioscience Inc. (Accro Bio), a clinical-stage biotechnology company pioneering the development of novel therapeutics for immune mediated diseases, today announced the dosing of their first patient in the Phase IIb clinical trial of ...

2026-09-20 18:00 3425

BioShanghai Week 2026 Opens -- Joining Forces to Build a Global Biopharmaceutical Innovation Ecosystem

SHANGHAI, Sept. 20, 2026 /PRNewswire/ -- A news report from Yicai Global: On September 17, the BioShanghai Week 2026 opened at Zhangjiang Science Hall in Shanghai. Themed "AI for Biopharma, Health ...

2026-09-20 13:11 2706

Jiahui Health Highlights China's Growing Role in Global Medical Tourism at WTO Public Forum 2026

GENEVA, Sept. 18, 2026 /PRNewswire/ -- China is seeing growing momentum in inbound medical tourism, driven by expanding access to innovative therapies, visa facilitation and the development of internationally oriented healthcare services, Dr. John K. Hsiang, Chairman of Jiahui Health Executive Co...

2026-09-18 21:00 3009

2026 Tang Prize Award Ceremony Honors Six Laureates

Outstanding Achievements for Global Well-Being and Our Shared Future TAIPEI, Sept. 18, 2026 /PRNewswire/ -- The 2026 Tang Prize Award Ceremony brought together all six laureates in Taipei on September 18, with five receiving their awards in person and Biopharmaceutical Science laureate Dr. Steve...

2026-09-18 19:56 781

A robust adjusted EBIT margin of 18.8%, driven by solid organic revenue growth of 7.4%

PARIS, Sept. 18, 2026 /PRNewswire/ --  Virbac Headquarters, Carros, France * H1 2026 delivered a robust revenue growth of +7.4% and an adjusted EBIT margin of 18.8% at CERS: ○  Revenue growth is coming from both segm...

2026-09-18 00:33 2754

ADVANCION RELEASES 2025 SUSTAINABILITY REPORT: "SAFE BY CHOICE. SUSTAINABLE BY DESIGN."

Advancion's fifth annual report highlights the Company's progress in safety, sustainable innovation and responsible operations BUFFALO GROVE, Ill., Sept. 17, 2026 /PRNewswire/ -- Advancion Corporation ("Advancion" or the "Company"), a global leader in life sciences buffers and proprietary specia...

2026-09-17 23:48 3039

New Peer-Reviewed Study Confirms Innovative Technology Shatters ESR's Four-Hour Deadline

ALCOR Scientific's iSED® analyzers reshape lab logistics and improve patient care for one of medicine's most widely used tests * Seven times longer stability, independently validated. ESR samples on ALCOR Scientific's iSED analyzer remained accurate for up to 28 hours at room temperature and 4...

2026-09-17 21:00 2452

There's No One-Size-Fits-All for Treating Older Adults with Cancer, According to New NCCN Patient Resource

New guideline for patients and caregivers explains the importance of assessments to tailor cancer care to every person, regardless of age. PLYMOUTH MEETING, Pa., Sept. 17, 2026 /PRNewswire/ -- Today, the National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers—is publ...

2026-09-17 20:20 1779

Dr. Alison Armour agrees to become Chief Medical Officer of Alpha Fusion, as Company Advances Integration of At-211 Businesses with Curadh MTR

— Combining Both Companies' Astatine At-211 Assets, Development Capabilities, and Supply Chains to Create a Global Targeted Alpha Therapy Company — TOKYO, Sept. 17, 2026 /PRNewswire/ -- Alpha Fusion Inc. ("Alpha Fusion"), a clinical-stage company with an advanced At-211 drug platform, and Curadh ...

2026-09-17 19:00 2819

111 Inc. Receives Unsolicited Preliminary Non-Binding Proposal to Acquire the Company

SHANGHAI, Sept. 17, 2026 /PRNewswire/ -- 111 Inc. ( "111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company in China, today announced that its Board of Directors (the "Board") has received an unsolicited preliminary non-binding proposal letter (the "Proposal") dat...

2026-09-17 16:25 6181

WuXi XDC Out-Licenses WuXiTecan-2 Payload-Linker Technology Platform to Ona Therapeutics to Advance Novel ADC Research and Development

SHANGHAI, Sept. 17, 2026 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specializing in antibody-drug conjugates (ADCs) and other bioconjugates, today announced an out-licensing collab...

2026-09-17 16:09 3046

Clarivate Reveals Citation Laureates 2026 Recognizing Transformative Scientific Breakthroughs

22 researchers honored for Nobel-class discoveries, including pioneers of GLP-1 medicines and other world-changing advances LONDON, Sept. 17, 2026 /PRNewswire/ -- Clarivate Plc ...

2026-09-17 15:05 3151

111, Inc. Announces Second Quarter 2026 Unaudited Financial Results

* Transition from An Asset-Heavy Business Model to An Asset-Light Business Model * Ongoing Investment and Adoption of AI Agents Making Workforce Streamlining Possible * Net Revenue of Promotional Products (1) Increased by 121% and Gross Profit Rose by 120% Year-over-Year * Total Marketpla...

2026-09-17 15:00 7057

Akeso's EGFR/TROP2 Bispecific ADC AK158D1 Granted NMPA Phase I Clearance for Advanced Solid Tumors, Marking Its Fourth Clinical-Stage ADC Candidate

HONG KONG, Sept. 17, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that AK158D1, its investigational next-generation bispecific antibody-drug conjugate (ADC) targeting EGFR and TROP2, has secured Phase I clinical trial clearance from the Center for Drug Evaluatio...

2026-09-17 14:34 2408
1 ... 9101112131415 ... 351